Camber Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Camber Capital Management’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-852,900	Closed	-$33.1M	–	39
2024 Q1	$33.1M	Sell	852,900 -197,100	-19%	-$6.9M	0.81%	22
2023 Q4	$32.3M	Hold	1,050,000	–	–	0.82%	23
2023 Q3	$23.5M	Hold	1,050,000	–	–	0.77%	30
2023 Q2	$22.6M	Hold	1,050,000	–	–	0.73%	28
2023 Q1	$25.2M	Hold	1,050,000	–	–	0.77%	25
2022 Q4	$24.4M	Hold	1,050,000	–	–	0.84%	25
2022 Q3	$16.8M	Hold	1,050,000	–	–	0.52%	40
2022 Q2	$18.6M	Hold	1,050,000	–	–	0.81%	28
2022 Q1	$21.4M	Hold	1,050,000	–	–	0.77%	30
2021 Q4	$19.6M	Sell	1,050,000 -950,000	-48%	-$18.5M	0.67%	30
2021 Q3	$39.5M	Hold	2,000,000	–	–	1.22%	30
2021 Q2	$47.3M	Hold	2,000,000	–	–	1.59%	27
2021 Q1	$47.4M	Hold	2,000,000	–	–	1.63%	20
2020 Q4	$40.1M	Hold	2,000,000	–	–	1.41%	23
2020 Q3	$41.6M	Hold	2,000,000	–	–	2.2%	15
2020 Q2	$35M	Hold	2,000,000	–	–	2%	16
2020 Q1	$32.7M	Buy	+2,000,000	New	+$41.3M	1.95%	19

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Camber Capital Management's COLL Position: Q2 2024 in Review

Camber Capital Management sold out of Collegium Pharmaceutical (COLL) in Q2 2024, closing a stake of 852,900 shares — an estimated $33.1M sold.

Camber Capital Management first reported a position in COLL in Q1 2020 and held it in 17 quarters. The position peaked at $47.4M in Q1 2021. 229 funds tracked by Wall St. Rank hold COLL as of Q2 2024.

Camber Capital Management reported no remaining Collegium Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Camber Capital Management sold 852,900 Collegium Pharmaceutical shares in Q2 2024, an estimated $33.1M.
Camber Capital Management first reported a position in Collegium Pharmaceutical in Q1 2020 and held it in 17 quarters.
Camber Capital Management's Collegium Pharmaceutical position peaked at $47.4M in Q1 2021.
229 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2024.

Based on Camber Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.